Filgrastime (G-CSF)

Phase 3Small molecule

MMinistry of Health, Brazil

Filgrastime (G-CSF) is one of 4 small molecule programs targeting Chagas cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chagas CardiomyopathyActive, not recruiting

Chagas CardiomyopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Chagas Cardiomyopathy

#DrugCompanyPhaseTrials

Zebeta

Teva

Phase 3

1 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

—3

Filgrastime (G-CSF)

MMinistry of Health, Brazil

Phase 3

1 4

Amiodarone Hydrochloride

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chagas cardiomyopathy1 trial

Cell Therapy in Chagas Cardiomyopathy

Terminated·MMinistry of Health, Brazil·Phase 3·NCT00349271·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Filgrastime (G-CSF). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Filgrastime (G-CSF) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Filgrastime (G-CSF). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ministry of Health, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMinistry of Health, Brazil

Filgrastime (G-CSF)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chagas cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News